Inflammatory bowel disease

被引:0
|
作者
Herrlinger, K [1 ]
Stange, EF [1 ]
机构
[1] Robert Bosch Krankenhaus, D-70376 Stuttgart, Germany
来源
INTERNIST | 2003年 / 44卷 / 09期
关键词
inflammatory bowel disease; Crohn's disease; ulcerative colitis; immunosuppression; infliximab;
D O I
10.1007/s00108-003-1008-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The etiology of inflammatory bowel diseases is still unknown. However, there seems to be a primary defect in mucosal barrier function resulting in a chronic inflammatory process. Both entities, Crohn's disease and ulcerative colitis show characteristic differences in clinical presentation and laboratory, radiological as well as endoscopical criteria. In some cases of the so called indeterminate colitis a clear distinction may not be possible. Therapy of inflammatory bowel disease aims for a suppression of the mucosal inflammation. Site, extent and especially the course of disease are crucial for the decision when and how to treat the patient. According to the patient's symptoms and disease history topical or systemic application of mesalazine or corticosteroids are used. In case of an intermittent course of disease treatment of the single flare should be started whereas in chronic active disease an immunosuppression with azathioprine, methotrexate or in therapy refractory cases infliximab is warranted.
引用
收藏
页码:1151 / 1171
页数:21
相关论文
共 50 条
  • [41] Necessity of phenotypic classification of Inflammatory Bowel Disease
    Louis, Edouard
    Van Kemseke, Catherine
    Reenaers, Catherine
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 : S2 - S7
  • [42] Endoscopy as a Prognostic Marker in Inflammatory Bowel Disease
    Camus, Marine
    Pariente, Benjamin
    Dray, Xavier
    Allez, Matthieu
    Marteau, Philippe
    DIGESTIVE DISEASES, 2013, 31 (3-4) : 351 - 356
  • [43] Biologics in inflammatory bowel disease: what are the data?
    Cote-Daigneault, Justin
    Bouin, Mickael
    Lahaie, Raymond
    Colombel, Jean-Frederic
    Poitras, Pierre
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2015, 3 (05) : 419 - 428
  • [44] Primary Care of the Patient with Inflammatory Bowel Disease
    Park, Jean R.
    Pfeil, Sheryl A.
    MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (05) : 969 - +
  • [45] Skin manifestations of pediatric inflammatory bowel disease
    Martin de Carpi, J.
    Chavez Caraza, K.
    Vicente Villa, M. A.
    Gonzalez Ensenat, M. A.
    Vilar Escrigas, P.
    Vila Miravet, V.
    Guallarte Alias, P.
    Varea Calderon, V.
    ANALES DE PEDIATRIA, 2009, 70 (06): : 570 - 577
  • [46] Inflammatory bowel disease surgery in the biologic era
    Ferrari, Linda
    Krane, Mukta K.
    Fichera, Alessandro
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 8 (05): : 363 - 370
  • [47] Medical therapy for pediatric inflammatory bowel disease
    Sherlock M.E.
    Griffiths A.M.
    Current Gastroenterology Reports, 2012, 14 (2) : 166 - 173
  • [48] Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease
    Lakatos, Peter L.
    Lakatos, Laszlo
    Kiss, Lajos S.
    Peyrin-Biroulet, Laurent
    Schoepfer, Alain
    Vavricka, Stephan
    DIGESTION, 2012, 86 : 28 - 35
  • [49] Inflammatory bowel disease:: Current therapeutic options
    Domènech, E
    DIGESTION, 2006, 73 : 67 - 76
  • [50] Progress with infliximab biosimilars for inflammatory bowel disease
    Kurti, Zsuzsanna
    Gonczi, Lorant
    Lakatos, Peter L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (06) : 633 - 640